WO2001087272A3 - Encapsulating a toxic core within a non-toxic region in an oral dosage form - Google Patents

Encapsulating a toxic core within a non-toxic region in an oral dosage form Download PDF

Info

Publication number
WO2001087272A3
WO2001087272A3 PCT/US2001/040763 US0140763W WO0187272A3 WO 2001087272 A3 WO2001087272 A3 WO 2001087272A3 US 0140763 W US0140763 W US 0140763W WO 0187272 A3 WO0187272 A3 WO 0187272A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxic
drug
region
dosage form
core
Prior art date
Application number
PCT/US2001/040763
Other languages
French (fr)
Other versions
WO2001087272A2 (en
Inventor
Francis C Payumo
Chen-Chao Wang
Jill K Sherwood
Michael J Cima
Christopher M Gaylo
Donald C Monkhouse
Jaedeok Yoo
Original Assignee
Therics Inc
Massachusetts Inst Technology
Francis C Payumo
Wang Chen Chao
Jill K Sherwood
Michael J Cima
Christopher M Gaylo
Donald C Monkhouse
Jaedeok Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therics Inc, Massachusetts Inst Technology, Francis C Payumo, Wang Chen Chao, Jill K Sherwood, Michael J Cima, Christopher M Gaylo, Donald C Monkhouse, Jaedeok Yoo filed Critical Therics Inc
Priority to EP01937808A priority Critical patent/EP1286663B1/en
Priority to DE60116758T priority patent/DE60116758T2/en
Priority to JP2001583741A priority patent/JP5178982B2/en
Priority to AU2001263506A priority patent/AU2001263506A1/en
Priority to CA2408956A priority patent/CA2408956C/en
Publication of WO2001087272A2 publication Critical patent/WO2001087272A2/en
Publication of WO2001087272A3 publication Critical patent/WO2001087272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder. This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.
PCT/US2001/040763 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form WO2001087272A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01937808A EP1286663B1 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form
DE60116758T DE60116758T2 (en) 2000-05-18 2001-05-18 Encapsulation of a toxic to a non-toxic region in an oral formulation
JP2001583741A JP5178982B2 (en) 2000-05-18 2001-05-18 Encapsulation of the toxic core in a non-toxic region in an oral dosage form
AU2001263506A AU2001263506A1 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form
CA2408956A CA2408956C (en) 2000-05-18 2001-05-18 Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20589600P 2000-05-18 2000-05-18
US60/205,896 2000-05-18

Publications (2)

Publication Number Publication Date
WO2001087272A2 WO2001087272A2 (en) 2001-11-22
WO2001087272A3 true WO2001087272A3 (en) 2002-04-18

Family

ID=22764098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040763 WO2001087272A2 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form

Country Status (9)

Country Link
US (2) US7276252B2 (en)
EP (1) EP1286663B1 (en)
JP (2) JP5178982B2 (en)
AT (1) ATE315930T1 (en)
AU (1) AU2001263506A1 (en)
CA (1) CA2408956C (en)
DE (1) DE60116758T2 (en)
ES (1) ES2257412T3 (en)
WO (1) WO2001087272A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
WO2003037607A1 (en) * 2001-10-29 2003-05-08 Therics, Inc. A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form
WO2003041690A2 (en) * 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
CA2464653C (en) * 2001-10-29 2011-10-18 Therics, Inc. System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
EP1503741B1 (en) * 2002-05-06 2008-09-10 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (en) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド Antibiotic preparations, their use and preparation
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotic product, use and formulation thereof
US20050087902A1 (en) * 2003-10-28 2005-04-28 Isaac Farr Alginate-based materials, methods of application thereof, and systems for using the alginate-based materials
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
US7566747B2 (en) * 2004-05-07 2009-07-28 The Board Of Trustees Of The University Of Illinois Wax particles for protection of activators, and multifunctional autonomically healing composite materials
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
TWI428271B (en) * 2004-06-09 2014-03-01 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
JPWO2006004069A1 (en) * 2004-07-01 2008-04-24 日本碍子株式会社 Microcapsule and method for producing the same
JP2008505124A (en) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション Pulse delivery tablets
ES2555152T3 (en) * 2004-11-26 2015-12-29 Aprecia Pharmaceuticals Co. Dosage forms printed in three dimensions
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US7612152B2 (en) * 2005-05-06 2009-11-03 The Board Of Trustees Of The University Of Illinois Self-healing polymers
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US7723405B2 (en) * 2006-01-05 2010-05-25 The Board Of Trustees Of The University Of Illinois Self-healing coating system
GB0608402D0 (en) * 2006-04-28 2006-06-07 Diurnal Ltd Thyroid treatment
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7569625B2 (en) * 2006-06-02 2009-08-04 The Board Of Trustees Of The University Of Illinois Self-healing elastomer system
US8394921B2 (en) 2006-07-25 2013-03-12 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
US20080299391A1 (en) * 2007-05-31 2008-12-04 White Scott R Capsules, methods for making capsules, and self-healing composites including the same
WO2009007969A2 (en) * 2007-07-09 2009-01-15 Colint Ltd. Portable hydration apparatus
US20090181254A1 (en) * 2008-01-15 2009-07-16 The Board Of Trustees Of The University Of Illinois Multi-capsule system and its use for encapsulating active agents
JP2011074015A (en) * 2009-09-30 2011-04-14 Tomita Pharmaceutical Co Ltd Solid preparation and method for preparing the same
DE102010051743B4 (en) 2010-11-19 2022-09-01 C. Miethke Gmbh & Co. Kg Programmable hydrocephalus valve
SG10201505503WA (en) * 2011-05-25 2015-09-29 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices
US8414654B1 (en) * 2011-11-23 2013-04-09 Amendia, Inc. Bone implants and method of manufacture
CN102551927A (en) * 2011-11-29 2012-07-11 上海大学 Embedded type graded drug release three-dimensional rack and preparation method thereof
KR101572009B1 (en) 2012-09-05 2015-11-25 아프레시아 파마슈티칼스 컴퍼니 Three-dimensional printing system and equipment assembly
US8888480B2 (en) 2012-09-05 2014-11-18 Aprecia Pharmaceuticals Company Three-dimensional printing system and equipment assembly
US20140099351A1 (en) * 2012-10-04 2014-04-10 Axxia Pharmaceuticals, Llc Process for making controlled release medical implant products
MX365914B (en) 2013-03-15 2019-06-20 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of topiramate.
EP2968994B1 (en) 2013-03-15 2018-08-15 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
WO2014143935A1 (en) * 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
WO2015023729A1 (en) 2013-08-16 2015-02-19 The Exone Company Three-dimensional printed metal-casting molds and methods for making the same
WO2015057761A1 (en) 2013-10-17 2015-04-23 The Exone Company Three-dimensional printed hot isostatic pressing containers and processes for making same
ES2745763T3 (en) 2013-12-23 2020-03-03 The Exone Co Methods and systems for three-dimensional printing using multiple binder fluids
EP3086922B1 (en) 2013-12-23 2022-03-09 The Exone Company Method of three-dimensional printing using a multi-component build powder
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
WO2015183796A1 (en) 2014-05-29 2015-12-03 The Exone Company Process for making nickel-based superalloy articles by three-dimensional printing
WO2016011098A2 (en) 2014-07-17 2016-01-21 The Exone Company Methods and apparatuses for curing three-dimensional printed articles
US9854828B2 (en) 2014-09-29 2018-01-02 William Langeland Method, system and apparatus for creating 3D-printed edible objects
US20180001551A1 (en) 2014-12-03 2018-01-04 The Exone Company Process for Making Densified Carbon Articles by Three Dimensional Printing
CA2987114A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodibleplug
AU2016310470A1 (en) 2015-08-21 2018-02-22 Aprecia Pharmaceuticals LLC Three-dimensional printing system and equipment assembly
CN108472249A (en) 2015-10-23 2018-08-31 林德拉有限公司 Stomach resident system and its application method for therapeutic agent sustained release
JP6878417B2 (en) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド Dosage forms and their use
CN107847398B (en) 2016-05-05 2019-05-07 南京三迭纪医药科技有限公司 Control the pharmaceutical dosage form of release
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
GB201620066D0 (en) 2016-11-28 2017-01-11 Ucl Business Plc Solid Pharmaceutical dosage formulations and processes
WO2018156141A1 (en) 2017-02-24 2018-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional (3d) printing a pharmaceutical tablet
GR1009361B (en) 2017-05-11 2018-09-17 Κωνσταντινος Ηλια Θεοδοσοπουλος A system for the production of tablets, granules and capsules via three-dimensional printing
WO2018218203A1 (en) 2017-05-26 2018-11-29 Philip Brunner Water soluble polymer compositions
US10350822B1 (en) 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
US11571391B2 (en) 2018-01-09 2023-02-07 Triastek, Inc. Oral drug dosage forms compromising a fixed-dose of an ADHD non-stimulant and an ADHD stimulant
DE102018107585B3 (en) * 2018-03-29 2019-03-28 Universität Rostock Device for producing 3D printed drug delivery systems with drug depots, and methods for manufacturing 3D printed drug delivery systems
IT201800004265A1 (en) 2018-04-06 2019-10-06 Apparatus and method for the automated production of customizable dosage forms.
JP2022508714A (en) 2018-10-15 2022-01-19 アプレシア・ファーマスーティカルズ・エルエルシー Methods and systems for forming dosage forms in packaging
CA3125779A1 (en) 2019-01-07 2020-07-16 Fritz Schmitt Process for producing a gaseous active ingredient or a gaseous active ingredient mixture, kit for use therein and gaseous composition
US11724486B2 (en) 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
JP2023533478A (en) 2020-06-26 2023-08-03 アプレシア・ファーマスーティカルズ・エルエルシー Rapidly dispersible tablet with internal cavity
TW202224672A (en) 2020-10-30 2022-07-01 大陸商南京三迭紀醫藥科技有限公司 Gastroretentive pharmaceutical dosage form
GB2608846A (en) * 2021-07-14 2023-01-18 Quay Pharmaceuticals Ltd Method and apparatus for additive manufacturing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009762A1 (en) * 1992-11-05 1994-05-11 Merck & Co., Inc. Drug delivery device
EP0659432A1 (en) * 1993-12-23 1995-06-28 Akzo Nobel N.V. Sugar-coated pharmaceutical dosage unit
EP0671167A1 (en) * 1994-02-10 1995-09-13 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
WO1998036739A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801203A (en) * 1951-03-22 1957-07-30 Byk Gulden Lomberg Chem Fab X-ray method of digestive enzyme diagnosis using protected core of contrast agent
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
DE69535432T2 (en) * 1994-04-22 2007-12-06 Astellas Pharma Inc. Colon-specific drug delivery system
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009762A1 (en) * 1992-11-05 1994-05-11 Merck & Co., Inc. Drug delivery device
EP0659432A1 (en) * 1993-12-23 1995-06-28 Akzo Nobel N.V. Sugar-coated pharmaceutical dosage unit
EP0671167A1 (en) * 1994-02-10 1995-09-13 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
WO1998036739A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof

Also Published As

Publication number Publication date
JP2012082224A (en) 2012-04-26
CA2408956C (en) 2011-07-12
US20020015728A1 (en) 2002-02-07
EP1286663B1 (en) 2006-01-18
DE60116758T2 (en) 2006-11-02
JP5178982B2 (en) 2013-04-10
CA2408956A1 (en) 2001-11-22
DE60116758D1 (en) 2006-04-06
US20060110443A1 (en) 2006-05-25
US7875290B2 (en) 2011-01-25
US7276252B2 (en) 2007-10-02
ES2257412T3 (en) 2006-08-01
WO2001087272A2 (en) 2001-11-22
ATE315930T1 (en) 2006-02-15
JP2003533470A (en) 2003-11-11
AU2001263506A1 (en) 2001-11-26
EP1286663A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
WO2001087272A3 (en) Encapsulating a toxic core within a non-toxic region in an oral dosage form
RU2743447C2 (en) Nicotine evaporation and inhalation devices
EP3678500B1 (en) Evaporation devices containing plant material
CA2302276A1 (en) Methods of treating capsules and dry, powdered pharmaceutical formulations
EP1693080A3 (en) Method and device for delivering aeroslized medicaments
AU2003212518A1 (en) Medicament delivery and packaging
JP2007513152A (en) Pharmaceutical product composed of tiotropium in a moisture-resistant container
WO1999064095A3 (en) Metering, packaging and delivery of pharmaceuticals and drugs
CA2445516A1 (en) Metered dose delivery device for liquid and powder agents
CA2352483A1 (en) Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
KR20070027691A (en) Dry powder inhaler
WO1998026828A3 (en) Medicament delivery and packaging
GB9410222D0 (en) Medicaments
WO2001036015A3 (en) Powder inhaler
CA2447099A1 (en) Delivery of compounds for the treatment of migraine through an inhalation route
JP2008502417A (en) Inhaler with pod
JP2008501473A (en) Guaranteeing the dose quality of inhalable drugs
NO332857B1 (en) Inhalation capsule and use of such
WO2002043693A3 (en) Pharmaceutical compositions for inhalation
CA2448927A1 (en) Pharmaceutical composition
WO2002102356A3 (en) Medicinal compositions comprising a melting core encapsulated in a hydroxypropylmethylcellulose film
TH75699A (en) Pharmaceutical formulation for dry powder inhalers Which contains active ingredients with low dosage strength

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2408956

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001263506

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001937808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937808

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001937808

Country of ref document: EP